Abstract: Background : The incidence of colorectal malignancies at a young age, and the absence of sufficient data to explain about it, including in terms of gene mutations that play a role. The research will be done here is to determine whether changes in mRNA expression of genes DCC ( deleted in colorectal cancer ) and p53 play a role in colorectal malignancy is less than 40 years of age. Researchers also will perform immunohistochemistry to look at protein expression of the gene and protein expression was evaluated whether these correlated with mRNA expression. 
Introduction
Colorectal carcinoma is the most common malignancy of the digestive tract. In the United States, more than 145,000 new cases diagnosed and 55,000 patients died each year. Colorectal carcinoma is the second cause of death after breast cancer in the United States. Comparisons between men and women are more or less the same, and the incidence has not changed over the past 20 years. [1, 2] Colorectal cancer is a genetic disorder in which 70% of cases are sporadic. There are several genes that play a role in the occurrence of colorectal cancer, but its role in preventing the progression is the DCC gene and p53. [3] [4] [5] [6] [7] [8] One factor that has a role in the process of protein expression of a gene is mRNA, whose role as a transcription factor. From the research that has been reported by ASCO in 2010, the mRNA expression of tumor suppressor genes can be used as one investigation for screening cases of malignancy colorectal, which is expected to reduce the number of false positives and false negatives of the examination at the level of protein expression. [5, 7, 9] The expression of these genes is indispensable in maintaining adhesion between cells, communication between cells, and as a control of apoptosis. To see whether the gene is still able to function as a tumor suppressor gene, we can examine mRNA expression level and the more modest examination of protein expression. [10] [11] [12] [13] [14] Examination of protein expression is said to still have a number of false positives and may not necessarily reflect whether a mutation or not. [12, 14] With the increasing incidence of colorectal malignancy at a young age, and lack of sufficient data to explain about it, including in terms of mutations in genes that play a role, research will be done here is to determine whether changes in mRNA expression DCC gene and p53 plays a role in colorectal malignancy less than 40 years old.
Methods
The paraffin block specimens were used for imunohistochemist examination.
By using RT-PCR technique, we examined the DCC and p53 mRNA expression from fresh tumor tissues of colon and rectal cancer patients. RNA isolation was done, following by qualitative RNA concentration examination and then we did realtime reverse transcriptase-PCR.
The tumor location was also evaluated in this study.
Data were analyzed using the Chi-square test, and the correlation was evaluated using Coefficient Contingentie
Results
From the results of the qRT-PCR to assess the DCC gene mRNA expression, obtained a mean increased expression in the age group less than 40 years old of 0.078, while the increase in mRNA expression obtained DCC higher in the age group more than 40 years old. In this study, we found rectum as the commonest site of colorectal cancer in both group of age although there was no correlation between age and sex or location. From table 3 and table 4 , we found correlation between protein and mRNA expression from DCC and p53 gene (p < 0.005).
Discussions
This study was conducted in 30 cases of colorectal malignancy compared between the age group less and more than 40 years old.
Comparison assessed protein and mRNA expression of two tumor suppressor genes that play a role in the development of colorectal malignancy were DCC and p53 genes.
Is associated with the expression of protein and mRNA of the gene p53, the age factor does not provide a meaningful relationship, the accumulation of p53 expression at both protein and mRNA more found in the age group over 40 years, but not statistically significant association (p> 0, 05). Meanwhile, when evaluated from the location factor for colorectal malignancies, are not obtained relationship with both protein and mRNA expression of two tumor suppressor genes such, it is consistent with studies have reported that the expression of protein and mRNA was not affected by the location of colorectal malignancy. However, the mechanism associated with the development of this malignancy is through LOH (loss of heterozigosity), there is a tendency to malignancy in the right colon, while the mechanisms of mismatch repair genes (MMR) tend to occur in the left colon with a less favorable prognosis. [11] [12] Additional information on the pathogenesis of colorectal malignancy of this research is the role of genes DCC (deleted in colorectal cancer) on the occurrence of colorectal malignancy in the age group ≤40 years. Previous research ever reported by Shibata, stated that the presence or absence of the protein expression of the DCC gene serves as a prognostic factor, in which case that is not accompanied by protein expression DCC gene has a worse prognosis, also described in the study, in the case of stage II colorectal malignancy that is not accompanied the DCC protein expression has the same prognosis with stage III colorectal malignancy. [12] [13] [14] [15] Other research data stating the role of this gene expression in predicting response to adjuvant chemotherapy, and otherwise also the role of thymidilate synthase as a predictor factor. [16] Examination at the protein level by immunohistochemistry technique to see whether or not the protein expression of the gene have a number of false positives and negatives when compared to examination in the mRNA level by RT-PCR examination. In this study, both immunohistochemical examination or RT-PCR that has been done to give consistent results, it can be considered to carry out checks on the protein level when another inspection has not been possible to do.
Gen DCC (deleted in colorectal cancer) is a tumor suppressor gene located on the long arm of chromosome 18 (18q), plays a role in suppressing the progression by maintaining adhesion between cells remain good, studies that have been reported to express the gene mutation is present in approximately 70% of cases of colorectal malignancy regardless of age. [17] [18] [19] In the present study, the age factor is evaluated to see if there is a different expression patterns among younger age groups in the age group over 40 years. Good views of the expression of protein and mRNA, the age group of less than 40 years old tend not to give expression, it is one of the factors increasing the incidence of malignancy Colorectal at a young age and patients present in advanced stages with a progression that is higher than the age group old. Other genes that have the same location with the DCC gene is Smad 4. [19] P53 gene located on the short arm of chromosome 17 (17P) is a tumor suppressor gene that plays a role in controlling apoptosis, several studies were performed to evaluate the role of this gene as a prognostic factor but not yet provide meaningful results. Mutations of these genes can be found in approximately 50% of cases. Examination of both immunohistochemistry and RT-PCR were performed to see his expression to assess the accumulation of mutant p53 contained in the cell nucleus. (20) This study can not provide meaningful information on the role of p53 expression in colorectal malignancy at age ≤ 40 years.
In the process of colorectal malignancy (adenoma-casinoma sequences) involving multiple gene mutations in each stage of development, from early to late adenoma adenoma and metastasis. The interaction between these genes could be evaluated, the research that has been done assessing the interactions between expression of K-ras, APC and p53. The results obtained are meaningful only on the interaction between p53 and APC. While the interaction between p53 and K-ras did not provide important role. [21] [22] [23] [24] [25] In this study, are associated with colorectal malignancy that occurs at a younger age (less than 40 years), not found a significant interaction between DCC and p53 expression. Given the age factor, the protein and mRNA expression of DCC is to play a role.
In clinical practice, examination of both immunohistochemistry and RT-PCR in the case of colorectal malignancy is not routinely performed, its use is still within the scope of clinical research. With the increasing number of reports research on the role of the expression of these genes in malignancy colorectal well as one of the factors prognosis and prediction of progression and response to chemotherapies, including the results of this study provide additional information on the malignancy of colorectal mainly in the age group ≤ 40 years, it could be possible the inspections began as a routine examination in clinical practice treatment of colorectal malignancy.
To test the hypothesis proposed in this study, performed statistical analysis with SPSS 19 used chi square analysis. Protein expression and mRNA of the DCC gene and p53 is mostly found in the age group> 40 years, however, only the expression of protein and mRNA DCC who have a role in relation to the age factor (p <0.05). The results of this study also showed that the protein expression of both genes were positively correlated with the results of the expression mRNAnya.
Although the studies were conducted in the same stadium, not all cases have the same expression pattern, especially in the age group ≤40 years, 27% are not accompanied by the expression of protein and mRNA DCC.
Anchored by the ferocity of the other organs of the digestive tract, there is a decrease in mRNA expression in gastric malignancy DCC, not only play a role in the emergence of malignancy itself, but also play a role in the occurrence of distant metastases to the liver. [26] This study concludes that the role of the protein and mRNA expression of the p53 gene in colorectal malignancy young age. Research reported by Shin IY in 2014, said the role of p53 expression to progression, including the spread to lymph nodes and distant metastases. Reported also the role of p53 against colorectal cancer stage. [27] p53 gene is said to be the guardian of the genome, protein p53 plays a role evaluate and recognize the damage of the cell and its function by inhibiting the cell cycle so that it is possible to perform DNA repair or, if not possible, will induce apoptosis.
Regulation of p53 gene can occur before the stage of translation, involving increased expression of the p53 gene as well as the stabilization of p53 mRNA expression. P53 gene has the ability to stimulate transcription itself, induced by internal promoter in the MDM2 gene, the gene products identified oncoprotein MDM2 acts as a negative regulator of the p53 gene. By binding to the gene p53, MDM2, inhibiting the ability to activate gene transcription process 53. So that in cases where a mutation in the p53 gene, accompanied by the absence of negative feedback resulting in overexpression of p53 gene mRNA.
Other research reported by Xu W, according to the results of this study, it was stated that p53 expression was not associated with age, gender and location of colorectal cancer. [28] From the standpoint of psychoneuroimmunology, greater volumes of the DCC protein expression (tumor suppressor gene) in the older group is made possible because the older people, stressor is lower, so that protein synthesis is not inhibited by a factor of cortisol. The release of cortisol is triggered by the presence of individual stress factors.
Akkiprik M, conducted a study in stage I and II colorectal cancer, stated that in addition to genetic testing, immunohistochemical examination can also be performed to assess the expression of the protein p53 abnormalities. Overexpression of p53 gene is more common in the left colon, so it is possible pathogenesis that is different from what happened in the colon right. At this stage, the expression of the p53 gene does not have a meaningful relationship with life expectancy. [29] In the colorectal cancer group were sporadic, Xiu-ying reported the role of alteration on chromosome 17P (p53 gene locations) against metastasis, progression and prognosis. [30] In this study, the protein and mRNA expression of mutant p53 genes more patients with colorectal cancer was found in the age group> 40 years, this is not consistent with the hypothesis put forward that the expression of mutant p53 protein and mRNA more found in the age group ≤40 years for in the younger age group, mutations occur early in the development stage. It is powered for the p53 gene are not spresifik in colorectal cancer, in some malignancies in other organs, the p53 gene is also mutated.
In the process of cancer, not only played by a mutation of the tumor suppressor gene, there are some other factors that come into play such defects or mutations in proto-oncogenes, increased apoptosis inhibitor gene activation and decreased activation of apoptosis stimulating genes. Suppresor genes inhibit tumor growth and inducing cell differentiation, so that the mutation of the gene will result in the protein becoming inactive and loss of inhibition of the progression of cancer development.
Colorectal cancer were found in younger age groups, in this study were less than 40 years old age, is a multi-factor process, factors remain a gene mutation in sporadic group. In addition to genetic factors, which play an important role in the process of colorectal cancer are environmental factors, food consumption habits low in fiber and high in animal protein is play a role in the process.
The presence of gene mutations that occur early in the development stage colorectal cancer patients younger age, followed by accumulation of mutations that exist primarily in tumor suppressor genes result in higher progression compared to patients with older age. Colorectal cancer treatment protocol that is used when no one has to use and distinguish the age factor in the delivery of adjuvant therapy. This is what makes a basic consideration for adjuvant chemotherapy in patients with colorectal cancer a young age which no longer obtain protein and mRNA expression of DCC gene. So expect after getting the handling of surgery and adjuvant therapy, we will be able to reduce the recurrence rate and may increase the rate of disease free survival. 
